Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 3
2018 3
2019 3
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial.
Seligmann JF, Wright-Hughes A, Pottinger A, Velikova G, Oughton JB, Murden G, Rizwanullah M, Price C, Passant H, Heudtlass P, Marshall H, Johnston S, Dodwell D. Seligmann JF, et al. Clin Oncol (R Coll Radiol). 2020 Oct;32(10):656-664. doi: 10.1016/j.clon.2020.06.003. Epub 2020 Jun 27. Clin Oncol (R Coll Radiol). 2020. PMID: 32600919 Clinical Trial.
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.
Seligmann JF, Elliott F, Richman S, Hemmings G, Brown S, Jacobs B, Williams C, Tejpar S, Barrett JH, Quirke P, Seymour M. Seligmann JF, et al. Ann Oncol. 2020 Aug;31(8):1021-1029. doi: 10.1016/j.annonc.2020.04.476. Epub 2020 May 6. Ann Oncol. 2020. PMID: 32387453 Free article. Clinical Trial.
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T; FOCUS4 Trial Investigators. Adams R, et al. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):162-171. doi: 10.1016/S2468-1253(17)30394-1. Epub 2017 Dec 16. Lancet Gastroenterol Hepatol. 2018. PMID: 29254887 Free PMC article. Clinical Trial.
13 results